COMMUNIQUÉS West-GlobeNewswire

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12/05/2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
12/05/2026
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable [...]
LiveWorld's New APP Research Council Gives Brands Direct Access to Frontline NP and PA Insights to Improve Relevance, Reach, and ROI
12/05/2026
Targets a long-overlooked gap in pharma marketing: the APP audience driving half of prescribing decisions CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a leader in [...]
Cellectis présentera des données cliniques sur lasmé-cel et éti-cel au congrès annuel de l’EHA 2026
12/05/2026
NEW YORK, 12 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12/05/2026
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with [...]
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
12/05/2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
12/05/2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden [...]
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
12/05/2026
The first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable disease control than current therapies. The agreement strengthens Boehringer [...]
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
12/05/2026
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib [...]
Becker’s Names Leap Distributors CEO Allen Mason to 2026 Great Leaders in Healthcare List
12/05/2026
DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Becker’s Hospital Review has named Leap Distributors Co-founder and CEO Allen Mason to the 2026 list of Great Leaders in Healthcare. Mason is included in the Companies section, [...]
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
12/05/2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and [...]
Mental Health Awareness Month: TPN.health Solves the Access Crisis Costing Self-Insured Stakeholders, Health Plans and Members the Care They Deserve
12/05/2026
NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) -- TPN.health , the operating system for behavioral health, is redefining what access to mental health care means for self-funded employers, health plans and the millions of [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
12/05/2026
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from [...]
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell [...]

Pages